SEC Filing Summary: ReShape Lifesciences Inc. (RSLS)
Business Context and Reporting Period
This Form 8-K was filed on July 19, 2022, by ReShape Lifesciences Inc., a Delaware corporation trading on the Nasdaq Capital Market under the symbol RSLS. The filing addresses two material events: a notice of non-compliance with Nasdaq listing standards and the resolution of a legal dispute.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial figure disclosed is a one-time cash payment of $1,000,000 made to settle a legal dispute with H.C. Wainwright & Co., LLC.
Material Changes and Events
- Nasdaq Delisting Notice: The Company received a notice from Nasdaq stating it failed to meet the $1.00 minimum bid price requirement (Rule 5550(a)(2)) based on the closing bid price over the last 30 consecutive business days.
- Compliance Timeline: The Company has an initial 180-day compliance period to regain the $1.00 bid price for 10 consecutive business days. Failure to comply may result in a second 180-day period if the Company elects to effect a reverse stock split.
- Legal Settlement: On July 22, 2022, the Company settled a breach of contract complaint filed by H.C. Wainwright & Co., LLC regarding prior capital raising transactions. The settlement required a $1,000,000 cash payment.
Outlook, Risks, and Management Commentary
Management intends to actively monitor listing standards and will consider available options to resolve the deficiency, including implementing a reverse stock split if necessary. The primary risk identified is the potential delisting from the Nasdaq Capital Market if the minimum bid price requirement is not met within the allotted compliance periods. The legal settlement resolves the previously disclosed litigation with Wainwright.
Investor Verification Checklist
- Verify the current trading price of RSLS to assess the likelihood of meeting the $1.00 bid price requirement within 180 days.
- Monitor future filings for any announcement of a reverse stock split to cure the listing deficiency.
- Review the Company's cash position to understand the impact of the $1,000,000 settlement payment on liquidity.
- Check for any additional disclosures regarding the terms of the settlement with H.C. Wainwright & Co., LLC.